Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

James A. Russell, FRCP, Leanne Kmet, MSc, Mary Lynn Savoie, MD, Nizar J. Bahlis, MD, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, Michelle Geddes, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Christopher Brown, MD, Jan Storek, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 5398.

https://doi.org/10.1182/blood.V108.11.5398.5398

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

James A. Russell, FRCP, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, M. Ahsan Chaudhry, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, Christopher Brown, MD, Alexander Balogh, MD, Jan Storek, MD, Michelle Geddes, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3009.

https://doi.org/10.1182/blood.V108.11.3009.3009

Published: 2006

Journal Articles

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Loree M. Larratt, MD, Michelle Geddes, MD, Jan Storek, MD, Mary Lynn Savoie, MD, Christopher Brown, MD, Nizar J. Bahlis, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3159.

https://doi.org/10.1182/blood.V108.11.3159.3159

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Michelle Geddes, MD, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Alexander Balogh, MD, Jan Storek, MD, Christopher Brown, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3140.

https://doi.org/10.1182/blood.V108.11.3140.3140

Published: 2006

Journal Articles

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

James A. Russell, FRCP, Loree M. Larratt, MD, A. Robert Turner, MD, M. Ahsan Chaudhry, MD, Oluyeme Jeje, MD, Donald Morris, MD, Christopher Brown, MD, Diana M. Quinlan, BN, Douglas A. Stewart, MD

Blood (2006) 108 (11): 2865.

https://doi.org/10.1182/blood.V108.11.2865.2865

Published: 2006

Journal Articles

Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.

James A. Russell, FRCP, Ahsan M. Chaudhy, MD, Oluyeme Jeje, MD, Diana Quinlan, RN, Douglas Stewart, MD, Donald Morris, MD, Nizhar J. Bahlis, MD, Lynne Savoie, MD, Christopher B. Brown, MD, Loree Larratt, MD, Michelle Geddes, MD, A. Robert Turner, MD

Blood (2004) 104 (11): 2313.

https://doi.org/10.1182/blood.V104.11.2313.2313

Published: 2004

Journal Articles

Individualized Once-Daily Dosing of Intravenous Busulfan: A Pharmacokinetic Study in Patients Undergoing Conditioning for Allogeneic Stem Cell Transplantation.

Shabal B. Kangarloo, MSc, Farrukh Naveed, BSc, Borje S. Andersson, MD, PhD, Diana Quinlan, BN, James A. Russell, FRCP

Blood (2004) 104 (11): 98.

https://doi.org/10.1182/blood.V104.11.98.98

Published: 2004

NARROW

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.

Individualized Once-Daily Dosing of Intravenous Busulfan: A Pharmacokinetic Study in Patients Undergoing Conditioning for Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.

Individualized Once-Daily Dosing of Intravenous Busulfan: A Pharmacokinetic Study in Patients Undergoing Conditioning for Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only